Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

June 3, 2025 expert reaction to observational study on low calorie diets and depressive symptoms . An observational study published in BMJ Nutrition, Prevention & Health looks at ...